miR-129-5p: A key factor and therapeutic target in amyotrophic lateral sclerosis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Amyotrophic lateral sclerosis (ALS) is a relentless and fatal neurological disease characterized by the selective degeneration of motor neurons. No effective therapy is available for this disease. Several lines of evidence indicate that alteration of RNA metabolism, including microRNA (miRNA) processing, is a relevant pathogenetic factor and a possible therapeutic target for ALS. Here, we showed that the abundance of components in the miRNA processing machinery is altered in a SOD1-linked cellular model, suggesting consequent dysregulation of miRNA biogenesis. Indeed, high-throughput sequencing of the small RNA fraction showed that among the altered miRNAs, miR-129-5p was increased in different models of SOD1-linked ALS and in peripheral blood cells of sporadic ALS patients. We demonstrated that miR-129-5p upregulation causes the downregulation of one of its targets: the RNA-binding protein ELAVL4/HuD. ELAVL4/HuD is predominantly expressed in neurons, where it controls several key neuronal mRNAs. Overexpression of pre-miR-129-1 inhibited neurite outgrowth and differentiation via HuD silencing in vitro, while its inhibition with an antagomir rescued the phenotype. Remarkably, we showed that administration of an antisense oligonucleotide (ASO) inhibitor of miR-129-5p to an ALS animal model, SOD1 (G93A) mice, result in a significant increase in survival and improved the neuromuscular phenotype in treated mice. These results identify miR-129-5p as a therapeutic target that is amenable to ASO modulation for the treatment of ALS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
miRBase: annotating high confidence microRNAs using deep sequencing data
Kozomara, A., & Griffiths-Jones, S. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1181 · Cited by 5,073
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis
Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall, J. C., Williams, K. L., Buratti, E., et al. (2008) · Science · doi:10.1126/science.1154584 · Cited by 2,630
TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis
Kabashi, E., Valdmanis, P. N., Dion, P., Spiegelman, D., McConkey, B. J., Velde, C. V., Bouchard, J.-P., Lacomblez, L., Pochigaeva, K., Salachas, F., et al. (2008) · Nature Genetics · doi:10.1038/ng.132 · Cited by 1,544
Majounie, E., Renton, A. E., Mok, K., Dopper, E. G., Waite, A., Rollinson, S., Chiò, A., Restagno, G., Nicolaou, N., Simon-Sanchez, J., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70043-1 · Cited by 1,210
Stargazin regulates synaptic targeting of AMPA receptors by two distinct mechanisms
Chen, L., Chetkovich, D. M., Petralia, R. S., Sweeney, N. T., Kawasaki, Y., Wenthold, R. J., Bredt, D. S., & Nicoll, R. A. (2000) · Nature · doi:10.1038/35050030 · Cited by 1,111
Distribution of miRNA expression across human tissues
Ludwig, N., Leidinger, P., Becker, K., Backes, C., Fehlmann, T., Pallasch, C., Rheinheimer, S., Meder, B., Stähler, C., Meese, E., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw116 · Cited by 968
Packer, A. N., Xing, Y., Harper, S. Q., Jones, L., & Davidson, B. L. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2390-08.2008 · Cited by 679
Cerebellar neurodegeneration in the absence of microRNAs
Schaefer, A., O'Carroll, D., Tan, C. L., Hillman, D., Sugimori, M., Llinas, R., & Greengard, P. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070823 · Cited by 498
Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS
Butovsky, O., Siddiqui, S., Gabriely, G., Lanser, A. J., Dake, B., Murugaiyan, G., Doykan, C. E., Wu, P. M., Gali, R. R., Iyer, L. K., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62636 · Cited by 481
Cited by
Neuronal injuries in cerebral infarction and ischemic stroke: From mechanisms to treatment (Review)
Zhao, Y., Zhang, X., Chen, X., & Wei, Y. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.5070 · Cited by 634
RNA–Binding Protein HuD as a Versatile Factor in Neuronal and Non–Neuronal Systems
Jung, M., & Lee, E. K. (2021) · Biology · doi:10.3390/biology10050361 · Cited by 39
Profiling Small RNA From Brain Extracellular Vesicles in Individuals With Depression
Ibrahim, P., Denniston, R., Mitsuhashi, H., Yang, J., Fiori, L. M., Żurawek, D., Mechawar, N., Nagy, C., & Turecki, G. (2024) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae013 · Cited by 29
Boicean, A., Birsan, S., Ichim, C., Boeras, I., Roman-Filip, I., Blanca, G., Bacila, C., Fleaca, R. S., Dura, H., & Roman-Filip, C. (2023) · Biomedicines · doi:10.3390/biomedicines11072058 · Cited by 23
Barbosa, M., Santos, M., de Sousa, N., Duarte-Silva, S., Vaz, A. R., Salgado, A. J., & Brites, D. (2022) · Biomedicines · doi:10.3390/biomedicines10092120 · Cited by 14
“Some works have evidenced an increased lifespan of mice [20–23], followed by an improvement in MN survival [21,22] and muscle strength [21,23].”
Background
Metadata
- Authors
- Loffreda, A., Nizzardo, M., Arosio, A., Ruepp, M.-D., Calogero, R. A., Volinia, S., Galasso, M., Bendotti, C., Ferrarese, C., Lunetta, C., Rizzuti, M., Ronchi, A. E., Mühlemann, O., Tremolizzo, L., Corti, S., & Barabino, S. M. L.
- Venue
- Progress in Neurobiology
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 190
- Pages
- 101803
- ISSN
- 0301-0082 (ISSN-L)
- OpenAlex
- W3018861406
- Cited by
- 61
- References
- 36
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: miR-129-5p: A key factor and therapeutic target in amyotrophic lateral sclerosis. https://app.cochat.ai/papers/10.1016/j.pneurobio.2020.101803
- The paper
- Loffreda, A., Nizzardo, M., Arosio, A., Ruepp, M.-D., Calogero, R. A., Volinia, S., Galasso, M., Bendotti, C., Ferrarese, C., Lunetta, C., Rizzuti, M., Ronchi, A. E., Mühlemann, O., Tremolizzo, L., Corti, S., & Barabino, S. M. L. (2020). miR-129-5p: A key factor and therapeutic target in amyotrophic lateral sclerosis. Progress in Neurobiology. https://doi.org/10.1016/j.pneurobio.2020.101803
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.